A New Hope for Patients with Advanced Gastric and Pancreatic Cancers<\/i><\/p>\n
SHANGHAI<\/span>, April 9, 2026<\/span> \/PRNewswire\/ —\u00a0A groundbreaking new CAR-T cell therapy<\/b> for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.<\/p>\n The therapy, known as satri-cel (CT041)<\/b>, is the world’s first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2<\/b>, a biomarker commonly found in gastric (stomach) and pancreatic cancers.<\/p>\n A New Era in Cancer Treatment<\/b><\/p>\n CAR-T therapy is a highly personalized treatment that uses a patient’s own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.<\/p>\n While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors<\/b>, where effective options have historically been limited.<\/p>\n Promising Clinical Results<\/b><\/p>\n Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers:<\/p>\n These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy.<\/p>\n Addressing a Major Unmet Need<\/b><\/p>\n Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes.<\/p>\n This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options<\/b>.<\/p>\n Who May Benefit<\/b><\/p>\n This therapy may be suitable for patients who:<\/p>\n Each patient will undergo a detailed medical evaluation to determine suitability.<\/p>\n Looking Ahead<\/b><\/p>\n This therapy represents a milestone in oncology<\/b>, opening the door for CAR-T treatments beyond blood cancers and into solid tumors.<\/p>\n Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types.<\/p>\n Contact Information<\/b><\/p>\n For more information, teleconsultation appointments and eligibility assessments please contact:<\/p>\n Jiahui Japanese Service Email: jih.jpcrm@jiahui.com<\/a>\u00a0<\/p>\n Full article: https:\/\/jiahui.com\/en\/news\/200<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":" <\/p>\n A New Hope for Patients with Advanced Gastric and Pancreatic Cancers<\/i><\/p>\n SHANGHAI<\/span>, April 9, 2026<\/span> \/PRNewswire\/ —\u00a0A groundbreaking new CAR-T cell therapy<\/b> for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.<\/p>\n The therapy, known as satri-cel (CT041)<\/b>, is the world’s first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2<\/b>, a biomarker commonly found in gastric (stomach) and pancreatic cancers.<\/p>\n A New Era in Cancer Treatment<\/b><\/p>\n CAR-T therapy is a highly personalized treatment that uses a patient’s own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.<\/p>\n While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors<\/b>, where effective options have historically been limited.<\/p>\n Promising Clinical Results<\/b><\/p>\n Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers:<\/p>\n These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy.<\/p>\n Addressing a Major Unmet Need<\/b><\/p>\n Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes.<\/p>\n This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options<\/b>.<\/p>\n Who May Benefit<\/b><\/p>\n This therapy may be suitable for patients who:<\/p>\n Each patient will undergo a detailed medical evaluation to determine suitability.<\/p>\n Looking Ahead<\/b><\/p>\n This therapy represents a milestone in oncology<\/b>, opening the door for CAR-T treatments beyond blood cancers and into solid tumors.<\/p>\n Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types.<\/p>\n Contact Information<\/b><\/p>\n For more information, teleconsultation appointments and eligibility assessments please contact:<\/p>\n Jiahui Japanese Service Email: jih.jpcrm@jiahui.com<\/a>\u00a0<\/p>\n\n
\n
\n
\n